BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 2230873)

  • 1. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.
    Berd D; Maguire HC; McCue P; Mastrangelo MJ
    J Clin Oncol; 1990 Nov; 8(11):1858-67. PubMed ID: 2230873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
    Berd D; Mastrangelo MJ
    Cancer Invest; 1988; 6(3):337-49. PubMed ID: 3167614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide.
    Berd D; Maguire HC; Mastrangelo MJ
    Cancer Res; 1986 May; 46(5):2572-7. PubMed ID: 3697996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases.
    Berd D; Sato T; Cohn H; Maguire HC; Mastrangelo MJ
    Int J Cancer; 2001 Nov; 94(4):531-9. PubMed ID: 11745440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses.
    Berd D; Sato T; Mastrangelo MJ
    Cancer Immunol Immunother; 2002 Aug; 51(6):320-6. PubMed ID: 12111120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma.
    Dillman RO; Nayak SK; Barth NM; DeLeon C; Schwartzberg LS; Spitler LE; Church C; O'Connor AA; Beutel LD
    Cancer Biother Radiopharm; 1998 Jun; 13(3):165-76. PubMed ID: 10850352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
    Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
    J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. M-Vax: an autologous, hapten-modified vaccine for human cancer.
    Berd D
    Expert Rev Vaccines; 2004 Oct; 3(5):521-7. PubMed ID: 15485331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.
    Berd D; Sato T; Maguire HC; Kairys J; Mastrangelo MJ
    J Clin Oncol; 2004 Feb; 22(3):403-15. PubMed ID: 14691123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.
    Lotem M; Merims S; Frank S; Hamburger T; Nissan A; Kadouri L; Cohen J; Straussman R; Eisenberg G; Frankenburg S; Carmon E; Alaiyan B; Shneibaum S; Ozge Ayyildiz Z; Isbilen M; Mert Senses K; Ron I; Steinberg H; Smith Y; Shiloni E; Gure AO; Peretz T
    J Immunol Res; 2016; 2016():8121985. PubMed ID: 27294163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
    Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
    Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine.
    Hsueh EC; Gupta RK; Qi K; Morton DL
    J Clin Oncol; 1998 Sep; 16(9):2913-20. PubMed ID: 9738558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
    Dillman RO; Barth NM; VanderMolen LA; Garfield DH; De Leon C; O'Connor AA; Mahdavi K; Nayak SK
    Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma.
    Hsueh EC; Essner R; Foshag LJ; Ye W; Morton DL
    Ann Surg Oncol; 2002 Jun; 9(5):486-92. PubMed ID: 12052761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.
    Berd D; Mastrangelo MJ
    Cancer Res; 1988 Mar; 48(6):1671-5. PubMed ID: 2830969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active specific immunotherapy of Dukes B2 and C colorectal carcinoma: comparison of two doses of the vaccine.
    Jessup JM; McBride CM; Ames FC; Guarda L; Ota DM; Romsdahl MM; Martin RG
    Cancer Immunol Immunother; 1986; 21(3):233-9. PubMed ID: 2938738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
    Morton DL
    Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide.
    Elias EG; Suter CM; Fabian DS
    J Surg Oncol; 1997 Jan; 64(1):17-22. PubMed ID: 9040795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.
    Hsueh EC; Essner R; Foshag LJ; Ollila DW; Gammon G; O'Day SJ; Boasberg PD; Stern SL; Ye X; Morton DL
    J Clin Oncol; 2002 Dec; 20(23):4549-54. PubMed ID: 12454111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.